Special Issue

Kidney Diseases in Critical III Patients

Message from the Guest Editor

Critical patients are an important field of research. This kind of medical care requires special treatment, and in such a context as kidney diseases could worsen a patient's clinical course and outcome. During hospitalization in critical care units, the onset of an acute kidney disease increases mortality. The pathophysiology of AKI in critically ill patients is complex and multifactorial, where an imbalance of electrolytes and fluids, heart failure, anemia, and other conditions require particular expertise and multiple approaches in which nephrologists should be involved. Diagnostics, especially noninvasive and bedside methods, are fundamental for specialists to take the best therapeutic approach, which could also require extracorporeal methods that should be adapted to these frail patients.

Guest Editor

Dr. Caterina Carollo

Unit of Nephrology and Dialysis, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), Hypertension Excellence Centre, University of Palermo, 90133 Palermo, Italy

Deadline for manuscript submissions

28 February 2026



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/226533

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).